Sentences with phrase «continue at our current rate»

We expect additional branch closures will lower costs further, but we don't expect that cost reductions will continue at current rates.

Just as Thomas Malthus had shown how population had the capacity to increase faster than the food supply, so this computer - based report concluded that world order would collapse if population growth, industrial expansion, increased pollution and the depletion of natural resources were to continue at current rates.

If Kane continues at his current rate then bids of note could be registered in the summer but if they hold off such moves then they will have done well but who would bet against Tottenham having lost the forward by the time the 2016/17 season kicks off?

So slow, in fact, that if it continues at its current rate, Buffalo will drop out of the U.S.'s 50 largest metropolitan areas by the year 2040, according to a new report.

If they continue at the current rate, the backlog could take up to 42 years to clear.

Even if they continue at the current rate, the moon would only have lost 30 per cent of its water by mass when the sun becomes a red giant in 6 billion years.

Based on what we know, we can expect the rapid ice loss to continue for a long time yet, especially if ocean - driven melting of the ice shelf in front of Pine Island Glacier continues at current rates,»

Time is running out: if global warming continues at its current rate, glaciers at an altitude below 3,500 metres in the Alps and 5,400 metres in the Andes will have disappeared by the end of the end of the 21st century.

If smoking continues at the current rate among U.S. youth, one in every 13 person younger than 18 is projected to die prematurely of a smoking - related illness.

«Our model assumes «business as usual» in the province, with high carbon emissions and climate change continuing at the current rate.

For every 100 people in the US, there will be six additional sleepless nights per year by 2050, if global warming continues at its current rate.

In other words, if greenhouse gas emissions continue at current rates, the world would see an extreme La Niña event every 13 years, rather than every 23 years.

The researchers claimed that changing weather patterns would commit up to 37 percent of the world's species to extinction by 2050 — far more than would go extinct if we continued at the current rate of habitat destruction.

Potential annual damages are shown on the county - level in a scenario in which emissions of greenhouse gasses continue at current rates.

But even considering Amazon's reported sales trends, it'll take years yet for physical books to be relegated to a tiny minority, which also assumes the incredible growth in e-book sales continues at its current rate.

It's obvious that economic and population growth can't continue at current rates without crashing into finite resource limits with painful results, and possibly abrupt reductions in growth.

But if global warming continues at its current rate, the Intergovernmental Panel on Climate Change estimates, the glaciers could be mostly gone from the mountains by 2035.

You could argue the paleo isn't refined enough for the current period, but there is nothing to suggest that the current warming will not continue at its current rate as long as we continue to emit.

If things continued at their current rate there wouldn't be much of a problem for a very long time.

That's what my calculation suggests, but over on the other thread, tonto points out that if uptake continues at the current rate (which would make sense if it is a concentration - dependent process) then halving emissions could bring the net change in concentration down to zero — basically, since half of our emissions are now going into sinks, if we cut emissions in half, all of it would.

If ocean acidification continues at the current rate, many species at the bottom of the food chain, as well as corals, could face extinction.

Under one recent analysis, the 2 - degree budget would be used up in 20 years if emissions continue at current rates.

In the other scenario, fossil fuel emissions continue at current rates unchecked and the global temperature increases 3.4 degrees Celsius.

Even if the earth's temperature had stayed the same or even decreased slighty over this time, ask yourself this: given what we know about the greenhouse effect and the levels of CO2 gases the world is creating, would you not be concerned that if we continue at the current rate, things are gonna get a hotter, eventually?

If terrestrial storage continues at its current rates, the projections could be changed by 0.21 to 0.11 m. For an average of the AOGCMs, the SRES scenarios give results that differ by 0.02 m or less for the first half of the 21st century.

Many of these cities will be submerged ice melt continues at its current rate (which is already greatly outstripping the highest - end IPCC projections — e.g. see here.

«You hate to sound alarmist, you hate to even consider that it could happen,» she explained, «but if the poaching continues at the current rate we could eventually see rhino go extinct.

The researchers claimed that changing weather patterns would commit up to 37 percent of the world's species to extinction by 2050 — far more than would go extinct if we continued at the current rate of habitat destruction.

Second: allowing fossil fuel production to continue at current rates for a while longer, followed by a sudden and severe termination of the sector, with dire consequences for both jobs and economies.

Payment will continue at the current rate (including the increase for the deceased qualified adult) for a period of 6 weeks following the death of the qualified adult, provided the surviving spouse, civil partner or cohabitant is in receipt of one of the payments listed at 1 above.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

The notes from the meeting show that a number of Fed officials feel that interest rates could begin to be raised from their current artificially low levels sooner than the current target of sometime in 2015 should certain economic factors continue to improve at a rapid pace.

At that rate, the current supply glut will continue and prices should stay within a relatively tight range.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

These risks include, in no particular order, the following: the trends toward more high - definition, on - demand and anytime, anywhere video will not continue to develop at its current pace or will expire; the possibility that our products will not generate sales that are commensurate with our expectations or that our cost of revenue or operating expenses may exceed our expectations; the mix of products and services sold in various geographies and the effect it has on gross margins; delays or decreases in capital spending in the cable, satellite, telco, broadcast and media industries; customer concentration and consolidation; the impact of general economic conditions on our sales and operations; our ability to develop new and enhanced products in a timely manner and market acceptance of our new or existing products; losses of one or more key customers; risks associated with our international operations; exchange rate fluctuations of the currencies in which we conduct business; risks associated with our CableOS ™ and VOS ™ product solutions; dependence on market acceptance of various types of broadband services, on the adoption of new broadband technologies and on broadband industry trends; inventory management; the lack of timely availability of parts or raw materials necessary to produce our products; the impact of increases in the prices of raw materials and oil; the effect of competition, on both revenue and gross margins; difficulties associated with rapid technological changes in our markets; risks associated with unpredictable sales cycles; our dependence on contract manufacturers and sole or limited source suppliers; and the effect on our business of natural disasters.

That gold is still holding at its current level — despite rising rates, despite a stock market that continues to rally — is «encouraging.»

It is safe to say that at current valuations, a continued extension of overvalued, overbought, overbullish conditions, with no reprieve from interest rate pressures, would keep us in a hedged stance.

Long bonds will end up being a very volatile investment at some point once rates or inflation rise from current levels, but intermediate - term bonds should continue to dampen stock market volatility.

With the continued dollar strength that we saw in this current year 2015, as we layered into additional hedges for fiscal»16 they were at less favorable rates.

The ECB has said it intends to continue bond purchases until at least September, to keep interest rates at current levels until «well past» the end of the program.

«If net income continued growing at this more modest pace, in lockstep with nominal GDP, corporations would not be able to continue growing dividends at current rates while keeping payout ratios constant.»

The economy is now at an advanced stage of its current expansion and has continued to show greater strength than had been generally expected, with real GDP growing at an average annual rate of more than 4 1/2 per cent, and domestic final demand at over 5 per cent, for the past three years.

As long as we see continued economic growth and inflation at current levels or higher, the current path of interest rate increases should continue.

Also, businesses are likely to find it increasingly difficult to continue to expand output at current rates without a pick - up in hiring.

If the current quarter continues at this pace, we will log the highest EPS beat rate since this reporting period in 2010.

The rising U.S. federal debt burden now ranks the U.S. among the most leveraged developed - market countries, and puts the U.S. at increased risk of a sovereign - debt credit rating downgrade if the current trend continues.

And looking to 2017, should we expect the headwind to continue in the out - year if rates stay at current levels?

With negative rates still in effect in Europe and the Fed's continuing on its current path of gradually raising rates, it makes perfect sense for European banks to continue to hold reserves at the Fed at a continuingly widening spread to take advantage of the risk - free arbitrage that currently exists.

According to an outside report, if the Episcopal Church continues declining at its current rate, it will be dead within 26 years.

If the increase in spending continues for India at its current rate, it is forecasted to surpass the U.K. by 2018.